Literature DB >> 18481293

Primary central nervous system lymphoma can be histologically diagnosed after previous corticosteroid use: a pilot study to determine whether corticosteroids prevent the diagnosis of primary central nervous system lymphoma.

Alyx B Porter1, Caterina Giannini, Timothy Kaufmann, Claudia F Lucchinetti, Wenting Wu, Paul A Decker, John L D Atkinson, Brian Patrick O'Neill.   

Abstract

The objective is to determine whether corticosteroid administration before biopsy prevents histopathological diagnosis of primary central nervous system lymphoma (PCNSL). A retrospective review was performed of immunocompetent PCNSL patients from 1985 to 2005. A total of 109 patients was identified. Sixty-eight (63.6%) patients received corticosteroids before diagnosis. Thirteen patients (of 109; 12%) had undergone repeat brain biopsy to confirm PCNSL. These included 8 (of 68) patients who had received corticosteroids (12%), and 5 (of 39) who had not (13%) (p = 1.0). The majority of PCNSL patients who received corticosteroids before diagnosis did not experience significant radiographic change or require second biopsy for diagnosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481293     DOI: 10.1002/ana.21366

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.

Authors:  R Mangla; B Kolar; T Zhu; J Zhong; J Almast; S Ekholm
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

2.  Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study.

Authors:  R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna
Journal:  J Neurooncol       Date:  2020-06-10       Impact factor: 4.130

3.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

Review 4.  New approaches in primary central nervous system lymphoma.

Authors:  Eleanor Fraser; Katherine Gruenberg; James L Rubenstein
Journal:  Chin Clin Oncol       Date:  2015-03

5.  The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes.

Authors:  Mattia Trunfio; Claudia Manini; Alice Trentalange; Andrea Boghi; Sabrina Audagnotto; Daniele Imperiale; Stefano Taraglio; Stefano Bonora; Giovanni Di Perri; Andrea Calcagno
Journal:  J Neurovirol       Date:  2019-06-18       Impact factor: 2.643

6.  Corticosteroid use in neuro-oncology: an update.

Authors:  Patrick Roth; Caroline Happold; Michael Weller
Journal:  Neurooncol Pract       Date:  2014-10-09

Review 7.  The Challenge of Primary Central Nervous System Lymphoma.

Authors:  Julia Carnevale; James L Rubenstein
Journal:  Hematol Oncol Clin North Am       Date:  2016-12       Impact factor: 3.722

Review 8.  CLIPPERS.

Authors:  Nicholas L Zalewski; W Oliver Tobin
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

10.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.